DBVT (DBV Technologies) Effective Interest Rate on Debt % : 24.10% (As of Mar. 2025)

View and export this data going back to 2014. Start your Free Trial

What is DBV Technologies Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. DBV Technologies's annualized positive value of Interest Expense for the quarter that ended in Mar. 2025 was $1.84 Mil. DBV Technologies's average total debt for the quarter that ended in Mar. 2025 was $7.65 Mil. Therefore, DBV Technologies's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2025 was 24.10%.

DBV Technologies Effective Interest Rate on Debt % Historical Data

The historical data trend for DBV Technologies's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DBV Technologies Effective Interest Rate on Debt % Chart

DBV Technologies Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

3.28

DBV Technologies Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															-	-	5.76	-	24.10

Competitive Comparison of DBV Technologies's Effective Interest Rate on Debt %

For the Biotechnology subindustry, DBV Technologies's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DBV Technologies's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where DBV Technologies's Effective Interest Rate on Debt % falls into.

Save Embed

;

Save Embed

;

DBV Technologies Effective Interest Rate on Debt % Calculation

DBV Technologies's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2024 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2023 )	+	Total Debt (A: Dec. 2024 ))	/ count )
=	-1 * 0	/	( (6.553	+	7.797)	/ 2 )
=	-1 * 0	/	7.175
=	0.00 %

where

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	4.526	+	2.027
=	6.553

	Total Debt (A: Dec. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	6.297	+	1.5
=	7.797

DBV Technologies's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2025 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Dec. 2024 )	+	Total Debt (Q: Mar. 2025 ))	/ count )
=	-1 * -1.844	/	( (7.797	+	7.506)	/ 2 )
=	-1 * -1.844	/	7.6515
=	24.10 %

where

	Total Debt (Q: Dec. 2024 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	6.297	+	1.5
=	7.797

	Total Debt (Q: Mar. 2025 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	6.525	+	0.981
=	7.506

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2025) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

DBV Technologies (NAS:DBVT) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

DBV Technologies Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of DBV Technologies's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

DBV Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (NAS:DBVT) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

0QAJ:UK DBV:France DBV:Germany DBV:Germany

Address

107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320

Website

https://www.dbv-technologies.com

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Executives

Pharis Mohideen	officer: Chief Medical Officer	C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Daniel Tasse	director, officer: Chief Executive Officer	C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809
Adora Ndu	director	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Virginie Boucinha	officer: Chief Financial Officer	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Timothy E Morris	director	ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Daniel B Soland	director	4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Daniele Guyot-caparros	director	C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Madduri Ravin Rao	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746
Michael Goller	director	C/O BAKER BROTHERS INVESTMENTS, 667 MADISON AVENUE, 21ST FLOOR, NEW YORK NY 10065
Rosen Michel De	director	C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341